Pictet Asset Management Holding SA Reduces Holdings in TransMedics Group, Inc. (NASDAQ:TMDX)

Pictet Asset Management Holding SA cut its stake in TransMedics Group, Inc. (NASDAQ:TMDX) by 5.8% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 4,434 shares of the company’s stock after selling 274 shares during the period. Pictet Asset Management Holding SA’s holdings in TransMedics Group were worth $276,000 as of its most recent SEC filing.

Several other large investors also recently bought and sold shares of TMDX. National Bank of Canada FI increased its position in shares of TransMedics Group by 174.7% during the third quarter. National Bank of Canada FI now owns 412 shares of the company’s stock worth $65,000 after purchasing an additional 262 shares in the last quarter. Hager Investment Management Services LLC acquired a new position in TransMedics Group during the fourth quarter worth approximately $33,000. Sachetta LLC acquired a new position in TransMedics Group during the fourth quarter worth approximately $40,000. AlphaQuest LLC purchased a new stake in TransMedics Group in the fourth quarter valued at approximately $52,000. Finally, Wilmington Savings Fund Society FSB acquired a new stake in shares of TransMedics Group in the third quarter valued at approximately $149,000. Institutional investors and hedge funds own 99.67% of the company’s stock.

TransMedics Group Stock Up 1.3 %

Shares of NASDAQ:TMDX opened at $76.37 on Friday. TransMedics Group, Inc. has a fifty-two week low of $55.00 and a fifty-two week high of $177.37. The company has a quick ratio of 7.33, a current ratio of 8.20 and a debt-to-equity ratio of 2.42. The firm’s 50-day simple moving average is $70.77 and its 200-day simple moving average is $82.09. The company has a market cap of $2.57 billion, a price-to-earnings ratio of 81.25 and a beta of 2.14.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on TMDX shares. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $104.00 target price on shares of TransMedics Group in a report on Tuesday, March 11th. Needham & Company LLC restated a “hold” rating on shares of TransMedics Group in a research note on Wednesday, March 26th. Finally, JPMorgan Chase & Co. reiterated a “neutral” rating and set a $75.00 target price (down previously from $116.00) on shares of TransMedics Group in a research note on Tuesday, December 17th. Three investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, TransMedics Group currently has a consensus rating of “Moderate Buy” and an average price target of $122.70.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.